Abstracts tagged "Cardiovascular"

Abstract Number: 0265 • ACR Convergence 2025
Influence of Menopausal Status on Coronary Artery Calcium Burden and Cardiovascular Computed Tomography Abnormalities in Inflammatory Arthritis
Mohammed Mohammed¹, Bindee Kuriya², Lihi Eder¹, Elsie Nguyen³, Shadi Ahktari⁴, Paula Harvey⁵, Wei Wu⁶ and Sohan Shahab⁷, ¹University of Toronto, Toronto, ON, Canada, ²University of Toronto - Toronto, Toronto, ON, Canada, ³University of Toronto, Toronto, ⁴University of Toronto Department of Medicine and Women's College Hospital, Toronto, Canada, ⁵University of Toronto Department of Medicine and Women's College Hospital, Toronto, ON, Canada, ⁶University of Toronto, Toronto, Canada, ⁷Women’s College Research Institute, Women’s College Hospital, Toronto, Canada
Background/Purpose: Patients with inflammatory arthritis (IA) have increased cardiovascular risk. Coronary artery calcium (CAC) scoring by computed tomography (CT) detects early coronary disease and structural…
Abstract Number: 0581 • ACR Convergence 2025
Effects of Apremilast on Body Mass Index, Weight, and HbA1c as Cardiometabolic Outcomes in Patients With Early Oligoarticular Psoriatic Arthritis in the FOREMOST Study
Philip J. Mease¹, Álvaro González Cantero², Jennifer Soung³, April Armstrong⁴, Joseph F Merola⁵, Fabian Proft⁶, Laure Gossec⁷, Dafna D. Gladman⁸, Laura Coates⁹, Lichen Teng¹⁰, Jimena Vázquez¹¹, Cynthia Deignan¹² and Arthur Kavanaugh¹³, ¹Department of Rheumatology, Providence-Swedish Medical Center and University of Washington, Seattle, WA, ²Department of Dermatology, Ramón y Cajal University Hospital, Madrid, Spain, ³Southern California Dermatology, Inc, Santa Ana, CA, USA, Santa Ana, ⁴University of California Los Angeles, Los Angeles, ⁵Department of Dermatology and Department of Medicine, UT Southwestern Medical Center, Dallas, TX, ⁶Department of Gastroenterology, Infectiology and Rheumatology (including Nutrition Medicine), Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany, ⁷Sorbonne Université, Pitié Salpêtrière Hospital, Paris, France, ⁸Schroeder Arthritis Institute, Krembil Research Institute, Toronto Western Hospital, Division of Rheumatology, Toronto, ON, Canada, ⁹Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, England, United Kingdom, ¹⁰Amgen Inc., Thousand Oaks, ¹¹Amgen Inc., Thousand Oaks, CA, ¹²Amgen, Inc., Agoura Hills, CA, ¹³University of California, San Diego, School of Medicine, San Diego, CA
Background/Purpose: The prevalence of cardiometabolic diseases, including obesity and diabetes, is higher in patients with psoriatic arthritis (PsA) than those without PsA.1,2 Metabolic syndrome is…
Abstract Number: 1112 • ACR Convergence 2025
Breaking Bones, Breaking Hearts: A FAERS Perspective on Osteoporosis Medications
Manush Sondhi¹, Namrata Singh², Julie Carkin¹ and Grant Hughes³, ¹University of Washington, Seattle, WA, ²University of Washington, Bellevue, WA, ³University of Washington, Lynnwood, WA
Background/Purpose: The cardiovascular risks associated with osteoporosis medications remain incompletely understood. Previous studies suggest that romosozumab (ROM) is most strongly associated with major adverse cardiovascular…
Abstract Number: 1528 • ACR Convergence 2025
Influence of Prednisone use over cardiovascular risk in patients with Systemic Lupus Erythematosus
Esteban C. Garza-Gonzalez¹, Fernanda M. Garcia-Garcia², Oscar Azael Garza-Flores³, Rebeca L. Polina-Lugo⁴, Leslie Y. Lopez-Cantú², Jose R Azpiri-Lopez⁵, Iris J. Colunga-Pedraza², Jesus Alberto Cardenas-de la Garza⁶, Dionicio A. Galarza-Delgado² and Diego Azamat Salcedo Almanza⁷, ¹Rheumatology Service, Hospital Universitario Dr. José Eleuterio González, Universidad Autónoma de Nuevo León, San Nicolas de los Garza, Nuevo Leon, Mexico, ²Rheumatology Service, Hospital Universitario Dr. José Eleuterio González, Universidad Autónoma de Nuevo León, Monterrey, Mexico, ³Rheumatology Service, Hospital Universitario Dr. José Eleuterio González, Universidad Autónoma de Nuevo León, Guadalupe, Mexico, ⁴Division of Rheumatology, University Hospital "Dr. Jose Eleuterio Gonzalez", Universidad Autonoma de Nuevo Leon, Monterrey, Nuevo León, Mexico, ⁵Cardiology Service, Hospital Universitario Dr. José Eleuterio González, Universidad Autónoma de Nuevo León, Monterrey, Mexico, ⁶Rheumatology Service, University Hospital “Dr. José Eleuterio González”, Universidad Autónoma de Nuevo León, Monterrey, México, Monterrey, Mexico, ⁷Radiology Service, Hospital Universitario “Dr. Jose Eleuterio Gonzalez”, Universidad Autonoma de Nuevo Leon, Monterrey, Nuevo Leon, Mexico
Background/Purpose: Systemic Lupus Erythematosus (SLE) is a chronic multisystem autoimmune disease associated with increased morbidity and mortality, particularly due to cardiovascular complications. Atherosclerotic cardiovascular disease…
Abstract Number: 1947 • ACR Convergence 2025
Coronary computed tomography incidental findings in rheumatoid arthritis.
Emmanuel Tapia López¹, Jessica Roldan Ortega², Evelyn Aranda Cano³, Itzel Palafox Sosa⁴, Luz Viruel⁵, Luis H Silveira⁶, Laura Aline Martinez-Martinez⁷ and Francisco Castillo-Castellon⁸, ¹Instituto Nacional de Cardiología Ignacio Chávez, Mexico City, Mexico, Naucalpan de Juarez, Estado de México, Mexico, ²INSTITUTO NACIONAL DE CARDIOLOGIA, Ciudad de México, Federal District, Mexico, ³Departament of rheumatology Instituto Nacional de Cardiología Ignacio Chávez, Ciudad de Mexico, Federal District, Mexico, ⁴Escuela Superior de Medicina-Instituto Politècnico Nacional, ciudad de mexico, Federal District, Mexico, ⁵Universidad Autónoma del Estado de Hidalgo, Tula de Allende, Hidalgo, Mexico, ⁶Instituto Nacional de Cardiología Ignacio Chávez, Mexico City, Mexico, Mexico City, Mexico, ⁷Rheumatology Department at National Institute of Cardiology Ignacio Chávez, Mexico City, Federal District, Mexico, ⁸Instituto Nacional de Cardiología Ignacio Chavez, Mexico
Background/Purpose: Patients with rheumatoid arthritis (RA) have a greater cardiovascular risk than does the general population. The coronary calcium score is a measure used to…
Abstract Number: 2394 • ACR Convergence 2025
Impact of Immunosuppressive Regimens on Major Cardiac Events in Patients with Systemic Lupus Erythematosus (SLE): A Survival Analysis
Emily Cosentino¹, Melissa Akselrad², Niurka Liranzo Tejera², Christine Lenchur², Takemichi Matsui², Adal Abonamah², Priscilla Abate Namnum¹, Olga Marushchak², Martin John³, Sophia Lutgen⁴, Celestine He⁵, Boluwatito Oladeinde⁶, Harleen Sidhu⁷ and Chrisanna Dobrowolski⁵, ¹Mount Sinai Morningside/West Hospitals, Icahn School of Medicine at Mount Sinai, New York, ²Mount Sinai Morningside/West Hospitals, Icahn School of Medicine at Mount Sinai, New York, NY, ³Icahn School of Medicine at Mount Sinai, New York, ⁴Mount Sinai Morningside/West Hospitals, Icahn School of Medicine at Mount Sinai, New York City, NY, ⁵Icahn School of Medicine at Mount Sinai, New York, NY, ⁶Icahn School of Medicine, New York, NY, ⁷Icahn School of Medicine at Mount Sinai/NYC H+H- Elmhurst, Queens, NY, Rego Park, NY
Background/Purpose: Cardiovascular events are a significant source of morbidity and mortality in SLE patients, occurring more frequently than in the general population owing to immune…
Abstract Number: 0315 • ACR Convergence 2025
Cross-sectional analysis of association between erosive hand osteoarthritis and cardiovascular disease.
Avanika Mahajan¹, Caroyln Harvey², Andy Abril³ and Megan Sullivan⁴, ¹Mayo Clinic, Scottsdale, ²Mayo Clinic, Phoenix, AZ, ³Mayo Clinic Florida, Jacksonville, ⁴Mayo Clinic Arizona, Scottsdale, AZ
Background/Purpose: Erosive hand osteoarthritis (EHOA) is an inflammatory subtype of hand OA that causes subchondral bone erosion and cortical destruction, often resulting in debilitating symptoms.…
Abstract Number: 0597 • ACR Convergence 2025
Low 25-hydroxyvitamin D Levels are Associated with Higher Mortality and More Cardiovascular Events in Systemic Lupus Erythematosus
Theerada Assawasaksakul¹, Andrea Fava², Daniel Goldman³, Laurence Magder⁴ and Michelle Petri³, ¹Johns Hopkins University School of Medicine, Baltimore, MD, ²Johns Hopkins University, Baltimore, MD, ³Johns Hopkins University School of Medicine, Timonium, MD, ⁴University of Maryland, Baltimore, Baltimore, MD
Background/Purpose: No studies have directly examined the link between 25-hydroxyvitamin D [25(OH)D] and cardiovascular outcomes in SLE. This study aimed to assess this association, hypothesizing…
Abstract Number: 1122 • ACR Convergence 2025
A Retrospective Study of Adverse Cardiovascular Events in Patients Started on JAK Inhibitors at Two Major Health Systems in Northeast Ohio: Analysis of the 2019 JAK Inhibitors FDA Boxed Warning for Increased Risk of Serious Heart-Related Problems
William Koch¹, Donald Anthony², Janeen Leon² and Nora G. Singer², ¹University Hospitals Parma Medical Center, Parma, OH, ²The MetroHealth System at Case Western Reserve University School of Medicine, Cleveland, OH
Background/Purpose: Janus kinase (JAK) inhibitors are immunosuppressive medications that target the JAK-STAT signaling pathway. Tofacitinib (Xeljanz) was the first JAK inhibitor approved for the treatment…
Abstract Number: 1552 • ACR Convergence 2025
Treatment With Anifrolumab Prevents Long-Term Cardiovascular Damage Accrual Compared With Real-World Standard of Care in Patients With Systemic Lupus Erythematosus: Findings From the LASER Study
Zahi Touma¹, Ian Bruce², Richard Furie³, Eric Morand⁴, Raj Tummala⁵, Shelly Chandran⁶, Gabriel Abreu⁷, Jacob Knagenhjelm⁷, Cathy Emmas⁸, Lyra Agustin⁸, Alessandra Venerus⁹, Tarana Mehdikhanova¹⁰, Zheyuan Yang¹⁰ and Miina Waratani⁸, ¹University of Toronto, Toronto, ON, Canada, ²Centre for Public Health, Faculty of Medicine, Health and Life Sciences, Queen's University, Belfast, Manchester, United Kingdom, ³Division of Rheumatology, Northwell Health, Great Neck, NY, ⁴Centre for Inflammatory Diseases, Monash University and Monash Health, Melbourne, Victoria, Australia, ⁵AstraZeneca, BioPharmaceuticals R&D, Gaithersburg, Gaithersburg, MD, ⁶AstraZeneca, Medical & Scientific Affairs, R&I, Mississauga, ON, Canada, ⁷AstraZeneca, BioPharmaceuticals R&D, Gothenburg, Sweden, ⁸AstraZeneca, BioPharmaceuticals Medical, Cambridge, United Kingdom, ⁹IQVIA, EMEA Real World Methods and Evidence Generation, Milan, Italy, ¹⁰IQVIA, EMEA Real World Methods and Evidence Generation, London, United Kingdom
Background/Purpose: Patients with systemic lupus erythematosus (SLE) can develop cardiovascular (CV) damage (angina, myocardial infarction, ventricular dysfunction, valvular disease, or pericarditis for 6 months/pericardiectomy) particularly…
Abstract Number: 1957 • ACR Convergence 2025
Correlates Between Cardiovascular Risk Scores with Coronary Microvascular Function and Plaque Burden in Rheumatoid Arthritis
Katherine Zhong¹, Lauren rusnak², Ying Qi³, Ilana Usiskin⁴, Gregory McDermott⁵, Brittany Weber⁶, Marcelo DiCarli⁵ and Katherine Liao², ¹Brigham and Women's Hospital, Short Hills, NJ, ²Brigham and Women's Hospital, Boston, MA, ³Brigham and Women’s Hospital, Boston, ⁴Division of Rheumatology, Inflammation, and Immunity, Department of Medicine, Brigham and Women's Hospital, Boston, ⁵Brigham and Women's Hospital, Boston, ⁶Brigham and Women's Hospital, DEDHAM, MA
Background/Purpose: A combination of traditional risk factors and chronic inflammation account for the excess cardiovascular risk (CV) observed in rheumatoid arthritis (RA), including atherosclerotic cardiovascular…
Abstract Number: 2413 • ACR Convergence 2025
Hydroxychloroquine and Adverse Cardiovascular Outcomes in Pregnant Patients with Systemic Lupus Erythematosus
Mariana Gonzalez-Treviño¹, Ashley L Ciosek¹, Genessis Maldonado¹, Catherine Deffendall², Tania Ruiz¹, Tracy Frech¹ and Rashmi Dhital³, ¹Vanderbilt University Medical Center, Nashville, TN, ²Vanderbilt University, Nashville, TN, ³Vanderbilt University Medical Center, Brentwood, TN
Background/Purpose: Hydroxychloroquine (HCQ) is a medication used in SLE during pregnancy. An adverse effect of HCQ includes cardiotoxicity. Hormonal changes during pregnancy may trigger SLE…
Abstract Number: 0346 • ACR Convergence 2025
Fibroblast Growth Factor-23 and Bone Status in Patients with Chronic Kidney Disease Compared to a Healthy Control Group and Its Relationship with Cardiovascular Risk
José Rodríguez gago¹, Carolina Tornero², Lina León³, María Luisa González-Casaus³, Luisa Fernanda Giraldo³, Gloria del Peso³, Diego Garrido³, Teresa López³, Mónica Coronado³, María Auxiliadora Bajo⁴, Sara García³, María Gema Serrano³, Marta Ossorio³, Alejandro Balsa³ and Pilar Aguado³, ¹Hospital Universitario La Paz, MADRID, ²Hospital La Paz, Madrid, Spain, ³Hospital Universitario La Paz, Madrid, Spain, ⁴Hospital Universitario de la Princesa - ISS Princesa, Madrid, Spain
Background/Purpose: Chronic kidney disease (CKD) is linked to increased vascular comorbidity and fracture risk. This study aims to assess bone status in CKD patients versus…
Abstract Number: 0598 • ACR Convergence 2025
Study of Long Term HCQ Safety on Cardiac Muscle Function in Patients with SLE and other Rheumatic Diseases
Jaspreet Bhatti¹, Kyu-In Lee², Nirali Sanghavi³, Stephen Zak⁴, Julia Ash⁵, James Miceli⁶, Kirk Sperber⁴, Stephen Pan⁷ and Amy Wasserman⁸, ¹Westchester Medical Center, Hopewell Junction, NY, ²Westchester Medical Center, Fort Lee, NJ, ³Westchester Medical Center, White Plains, NY, ⁴New York Medical College, Valhalla, ⁵Westchester Medical center, Dobbs Ferry, NY, ⁶Westchester Medical Center, Hawthorne, NY, ⁷Westchester Medical Center, Valhalla, ⁸New York Medical College at Westchester Medical Center, Armonk, NY
Background/Purpose: HCQ induced cardiomyopathy leading to heart failure is a rare but serious potential treatment complication. Currently there are no screening guidelines for detecting HCQ…
Abstract Number: 1137 • ACR Convergence 2025
Increased Risk of Cardiovascular Events and Mortality Related to Diffuse Idiopathic Skeletal Hyperostosis (DISH): A Systematic Review and Meta-Analysis
Pitchaporn Yingchoncharoen¹, Nattanicha Chaisrimaneepan², Miriam Paz³, Chanokporn Puchongmart¹, Ben thiravetyan¹, Panat Yanpiset¹ and Jerapas Thongpiya⁴, ¹Texas Tech Health Sciences Center, Lubbock, TX, ²Department of Medicine, Texas Tech University Health Sciences Center, Lubbock, TX, ³Texas Tech University Health Sciences Center, Lubbock, ⁴Texas Tech University Health Sciences Center at Lubbock Program, Lubbock, TX
Background/Purpose: Diffuse Idiopathic Skeletal Hyperostosis (DISH) is characterized by ossification and calcification of the entheses with prevalence increasing with age. It has been reported to…

1
2
3
…
38
Next Page »

All abstracts accepted to PRYSM are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 6:00 PM CT on March 18. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].